权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Investigation of Cdc34 Molecular Recognition by its Enzyme Partners, Uba1 and SCF Ligases.

通过其酶合作伙伴、Uba1 和 SCF 连接酶对 Cdc34 分子识别进行研究。

基本信息

批准号：
9912733
负责人：
Katelyn Williams
金额：
$ 4.74万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9912733
关键词：
Active Sites Address Antibodies Binding Biochemical Biochemical Genetics Biological Assay Cancer cell line Cell Cycle Cell Cycle Progression Cell Cycle Proteins Charge Complex Crystallization Cullin Proteins Cyclin-Dependent Kinase Inhibitor Data Development Electrostatics Enzymes F Box Domain Family Genetic Genetic Techniques Goals Human In Vitro Investigation Knowledge Laboratories Libraries Ligase Literature Malignant Neoplasms Mass Spectrum Analysis Modification Molecular Mutate Mutation Nature Pattern Phosphorylation Phosphorylation Site RBX1 gene Regulation Research Research Personnel Role S Phase Saccharomyces cerevisiae Proteins Serine Site Site-Directed Mutagenesis Structure Surface Techniques Therapeutic Ubiquitin Ubiquitin-Conjugating Enzymes Ubiquitination X-Ray Crystallography base cancer cell cell growth crosslink in vivo inhibitor/antagonist interest loss of function molecular recognition multicatalytic endopeptidase complex novel novel therapeutic intervention screening small molecule small molecule inhibitor structural biology targeted treatment ubiquitin-protein ligase yeast genetics

项目摘要

PROJECT SUMMARY Cdc34 is a key regulator in cell cycle progression at the G1 to S phase checkpoint1-3. It acts as an E2 ubiquitin conjugating enzyme that is first charged with ubiquitin by E1 enzyme, Uba1, and then functions with the SCF family of E3 enzymes to modify other cell cycle proteins with ubiquitin for targeted degradation by the proteasome4,5. In years since its discovery, Cdc34 dysregulation has been implicated in several types of cancer6-8. Many downstream targets of Cdc34 are cyclin-dependent kinase inhibitors such as p27 and p40 that are critically important for cancer progression9-14. Together, these findings have led to investigations of Cdc34 as a target for cancer therapeutics but a more directed approach, such as specifically targeting Cdc34 interactions with its enzyme partners is needed. However, a detailed structural understanding for molecular recognition of Cdc34 by its E1 partner, Uba1, and E3 ligase partners is not available. Further, regulation of Cdc34 is not completely understood. Previous studies have shown positive regulation of Cdc34 by phosphorylation; however, we have exciting preliminary data that implicates phosphorylation of residue serine 10 as a negative regulator of Cdc34 activity and this is supported in the literature by a phosphoproteome mass spectrometry screen that identified this residue in vivo15-18. Further, based on structural predictions we believe Ser10 residues on the surface of Cdc34 that interacts with both E1 and E3 enzymes. Thus, we aim to identify key residues in the molecular recognition of Cdc34 by its enzyme partners and hypothesize that phosphorylation of Ser10 will negatively regulate this molecular recognition through steric clash and electrostatic repulsions. Our hypothesis will be addressed through the following Specific Aims. Aim 1 will identify key residues for Cdc34 interaction with E1 and E3 enzyme partners. We will use x-ray crystallography in concert with biochemical and genetic techniques to accomplish this aim. Aim 2 will elucidate the regulatory effects of Cdc34 phosphorylation at residue Ser10. We will confirm the phosphorylation of Ser10 in vivo and examine the effects of S10D phosphomimetic mutation on molecular recognition of Cdc34 by its enzyme partners in vitro with biochemical assays and in vivo using yeast genetics.

项目总结